RA Capital Nexus Fund, L.P.: insider trades.
RA Capital Nexus Fund, L.P. reported 24 non-derivative transactions on 13 SEC ownership filings in Q3 2026: 11 open-market purchases ($5.1M) and 2 sales ($21.8M), across 4 companies.
- Transactions
- 24
- Purchases (P)
- 11
- Sales (S)
- 2
- Companies
- 4
- Name as filed
- RA Capital Nexus Fund, L.P.
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | Director, TenPercentOwner | 11 |
| Freenome, Inc. (FRNM) | Director, TenPercentOwner | 7 |
| Climb Bio, Inc. (CLYM) | Director, TenPercentOwner | 4 |
| Sionna Therapeutics, Inc. (SION) | Director, TenPercentOwner | 2 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-28 | Climb Bio, Inc. | M | 10,000 | $7.89 | 30,000 | Form 4 |
| 2026-09-28 | Climb Bio, Inc. | M | 40,000 | $1.29 | 70,000 | Form 4 |
| 2026-09-28 | Climb Bio, Inc. | M | 10,000 | $3.46 | 10,000 | Form 4 |
| 2026-09-28 | Climb Bio, Inc. | M | 10,000 | $3 | 20,000 | Form 4 |
| 2026-09-17 | Sionna Therapeutics, Inc. | S | 3,415,011 | $6.32 | 3,482,612 | Form 4 |
| 2026-09-17 | Sionna Therapeutics, Inc. | S | 33,800 | $7.46 | 3,448,812 | Form 4 |
| 2026-07-31 | Artiva Biotherapeutics, Inc. | P | 24,944 | $9.93 | 17,329,570 | Form 4 |
| 2026-07-29 | Artiva Biotherapeutics, Inc. | P | 20,824 | $9.99 | 17,304,626 | Form 4 |
| 2026-07-24 | Artiva Biotherapeutics, Inc. | P | 41,319 | $9.99 | 17,283,802 | Form 4 |
| 2026-07-23 | Artiva Biotherapeutics, Inc. | P | 59,880 | $9.96 | 17,242,483 | Form 4 |
| 2026-07-22 | Artiva Biotherapeutics, Inc. | P | 84,124 | $9.93 | 17,182,603 | Form 4 |
| 2026-07-21 | Artiva Biotherapeutics, Inc. | P | 120,582 | $9.55 | 17,098,479 | Form 4 |
| 2026-07-20 | Freenome, Inc. | A | 6,561,711 | — | 7,311,711 | Form 4 |
| 2026-07-20 | Freenome, Inc. | A | 970,950 | — | 970,950 | Form 4 |
| 2026-07-20 | Freenome, Inc. | A | 553,703 | — | 553,703 | Form 4 |
| 2026-07-20 | Freenome, Inc. | A | 908,103 | — | 908,103 | Form 4 |
| 2026-07-20 | Freenome, Inc. | A | 367,427 | — | 367,427 | Form 4 |
| 2026-07-20 | Freenome, Inc. | A | 4,918,411 | $10 | 12,230,122 | Form 4 |
| 2026-07-20 | Freenome, Inc. | A | 336,965 | $10 | 1,245,068 | Form 4 |
| 2026-07-17 | Artiva Biotherapeutics, Inc. | P | 7,882 | $8.95 | 16,977,927 | Form 4 |
| 2026-07-16 | Artiva Biotherapeutics, Inc. | P | 152,472 | $8.93 | 16,970,045 | Form 4 |
| 2026-07-13 | Artiva Biotherapeutics, Inc. | P | 6,522 | $8.94 | 16,817,543 | Form 4/A |
| 2026-07-13 | Artiva Biotherapeutics, Inc. | P | 6,552 | $8.94 | 16,817,573 | Form 4 |
| 2026-07-10 | Artiva Biotherapeutics, Inc. | P | 15,102 | $8.97 | 16,811,021 | Form 4 |
Questions
What stock did RA Capital Nexus Fund, L.P. buy or sell?
RA Capital Nexus Fund, L.P. reported 24 non-derivative transactions on 13 SEC ownership filings in Q3 2026: 11 open-market purchases ($5.1M) and 2 sales ($21.8M), across 4 companies.
Is RA Capital Nexus Fund, L.P. the same person as other filers with this name?
This page covers SEC CIK 1780117 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Plain-text version for agents and LLMs: /insiders/ra-capital-nexus-fund-l-p-1780117.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.